Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $122.1452W HIGH $186.12
Volume
362.47 K
Value Traded
153.70 M
Short % Float
4.94%
-0.7%Week
-8.35%1 Month
-19.72%3 Month
+10.31%6 Month
+64.72%5 Year
+1,205.83%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
14.52 B
EPS (TTM)
6.94
P/E Ratio
20.49
Ent. Value
14.06 B
Total Shares
101.69 M
Float Shares
100.47 M
Insiders
1.16%
Institutions
101.18%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
NBIX Catalyst Timeline
Dated clinical, regulatory and corporate events for Neurocrine Biosciences, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Neurocrine Biosciences, Inc.
1194Total events
9Upcoming
298Tier-1 (high impact)
2010 to 2027Coverage
Upcoming catalysts 2
Event history 50
▲IND ClearanceNBI-1117567IND
FDA IND Acceptance for Phase 2 study of NBI-1117567
Alzheimer's cognitionsource ↗
▲Milestone PaymentNBI-1117567Corporate
Nxera to receive US$10 million milestone payment upon IND Acceptance
▲Full ResultsValbenazineApprovedClinical Data
Publication of KINECT-PRO Phase 4 results in CNS Spectrums
tardive dyskinesiasource ↗
▲Trial InitiationNBIP-'1968Trial
Initiation of Phase 1 first-in-human clinical study evaluating NBIP-'1968
obesitysource ↗
▲Full ResultsCRENESSITYApprovedClinical Data
Two-year data from CAHtalyst Adult study announced
classic congenital adrenal hyperplasiasource ↗
▲Full ResultsClinical Data
New VYKAT XR data presented showing durable improvements in hyperphagia
Prader-Willi syndromesource ↗
▲Full ResultsValbenazineApprovedClinical Data
Post-hoc data from KINECT 4 trial announced
tardive dyskinesiasource ↗
●Trial InitiationCrinecerfontApprovedTrial
Phase 2 study initiated in children aged 3 months to under 4 years
classic congenital adrenal hyperplasiasource ↗
▲Quarterly UpdateValbenazineApprovedCorporate
INGREZZA 2026 net sales guidance raised to $2.825-$2.875 billion
tardive dyskinesia and chorea associated with Huntington's diseasesource ↗
●PublicationCRENESSITYApprovedPresentation
Publication of expert recommendations for glucocorticoid dose reduction after initiating CRENESSITY
classic congenital adrenal hyperplasiasource ↗
●Trial InitiationCrinecerfontApprovedTrial
Phase 2 study initiated in children aged 3 months to under 4 years
classic congenital adrenal hyperplasiasource ↗
▲Enrollment CompleteCrinecerfontApprovedTrial
Target enrollment achieved for Phase 2 study in EU in children from birth to under 2 years
classic congenital adrenal hyperplasiasource ↗
▲Full ResultsCRENESSITYApprovedClinical Data
Two-year data from CAHtalyst Adult study announced
classic congenital adrenal hyperplasiasource ↗
●PublicationCRENESSITYApprovedPresentation
Publication of expert recommendations for glucocorticoid dose reduction after initiating CRENESSITY
classic congenital adrenal hyperplasiasource ↗
▲Full ResultsClinical Data
New VYKAT XR data presented showing durable improvements in hyperphagia and behavioral symptoms
Prader-Willi syndromesource ↗
▲Full ResultsValbenazineApprovedClinical Data
Post-hoc data from KINECT 4 trial announced
tardive dyskinesiasource ↗
▲Late-BreakerPresentation
Late-breaking data at ENDO 2026 showing durable improvements after resuming VYKAT XR following randomized withdrawal
Prader-Willi syndromesource ↗
▲Oral PresentationPresentation
Oral presentation of Study C614 results at ENDO 2026
Prader-Willi syndromesource ↗
▲Poster PresentationPresentation
Poster: VYKAT XR Outcomes Compared to Real-World Data from PATH for PWS Natural History Study (HQ-CT Analysis)
Prader-Willi syndromesource ↗
▲Oral PresentationCRENESSITYApprovedPresentation
First retrospective case series of CRENESSITY in patients with classic CAH due to 11β-hydroxylase deficiency presented at ENDO 2026
classic congenital adrenal hyperplasia due to 11β-hydroxylase deficiencysource ↗
◆Poster PresentationCRENESSITYApprovedPresentation
Long-Term Risk of Cardiometabolic Comorbidities Associated with Glucocorticoid Exposure and Androgen Control in Classic Congenital Adrenal Hyperplasia: A Cox Proportional Hazards Analysis from the CAHtalog Registry
classic congenital adrenal hyperplasiasource ↗
◆Oral PresentationPresentation
Long-Term Risk of Cardiometabolic Comorbidities Associated with Glucocorticoid Exposure and Androgen Control in Classic CAH: Cox Proportional Hazards Analysis (Rapid Fire #ORF32-02 and Poster #MON-495)
classic congenital adrenal hyperplasiasource ↗
◆Poster PresentationPresentation
Modified Delphi Panel of U.S. Endocrinologists to Align on Minimum Clinically Important Difference in Glucocorticoid Dose and Other Key Considerations in Classic CAH (Poster #SAT-459)
classic congenital adrenal hyperplasiasource ↗
◆Oral PresentationPresentation
Impact of Long-Term Diazoxide Choline Extended-Release Treatment and the Prader-Willi Syndrome Profile Questionnaire
Prader-Willi syndromesource ↗
◆Poster PresentationCRENESSITYApprovedPresentation
Long-term Crinecerfont Enables Sustained Decreases in Glucocorticoid Doses — Clinical Outcomes in Children and Adolescents with Classic Congenital Adrenal Hyperplasia: 2-Year Results from CAHtalyst Pediatric
classic congenital adrenal hyperplasiasource ↗
◆Poster PresentationPresentation
Efficacy and Safety of Resuming Diazoxide Choline Extended-Release after 16-Week Randomized Withdrawal in Prader-Willi Syndrome (Study C614)
Prader-Willi syndromesource ↗
◆Poster PresentationCRENESSITYApprovedPresentation
Long-term Crinecerfont Treatment Reduced ACTH and 17-Hydroxyprogesterone — Clinical Outcomes in Children and Adolescents with Classic Congenital Adrenal Hyperplasia: 2-Year Results from CAHtalyst Pediatric
classic congenital adrenal hyperplasiasource ↗
◆Poster PresentationPresentation
A Modified Delphi Panel of U.S. Endocrinologists to Align on Minimum Clinically Important Difference in Glucocorticoid Dose and Other Key Considerations in Classic Congenital Adrenal Hyperplasia
classic congenital adrenal hyperplasiasource ↗
◆Oral PresentationPresentation
Goldman Sachs 47th Annual Global Healthcare Conference 2026 fireside chat
▲Oral PresentationValbenazineApprovedPresentation
Data presented at AADMD 24th Annual Education Conference showing functional and socio-emotional improvements with INGREZZA in TD patients with intellectual and developmental disabilities
tardive dyskinesiasource ↗
◆Oral PresentationPresentation
William Blair 46th Annual Growth Stock Conference fireside chat
◆Oral PresentationValbenazineApprovedPresentation
Presentation of real-world data on INGREZZA in mild TD at APA 2026
tardive dyskinesiasource ↗
◆Oral PresentationPresentation
Neurocrine Biosciences to present at Bank of America Health Care Conference 2026
▲PublicationCRENESSITYApprovedPresentation
Publication of expert recommendations for glucocorticoid dose reduction after initiating CRENESSITY
classic congenital adrenal hyperplasiasource ↗
▲Trial InitiationNBI-1117570Trial
Initiated Phase 2 clinical study of NBI-1117570 in adults with schizophrenia
Schizophreniasource ↗
▲Trial InitiationNBIP-'2118Trial
Initiation of Phase 1 first-in-human clinical study evaluating NBIP-'2118
obesitysource ↗
▲Oral PresentationCRENESSITYApprovedPresentation
Two-year data from CAHtalyst Pediatric presented at Pediatric Endocrine Society 2026 Annual Meeting
classic congenital adrenal hyperplasiasource ↗
●Debt Royalty FinancingCorporate
Entered into $1.0 billion senior secured revolving credit facility
▲PublicationValbenazineApprovedPresentation
Publication of peer-reviewed research on TDIS minimal clinically important difference in The Journal of Clinical Psychiatry
tardive dyskinesiasource ↗
▲Oral PresentationCRENESSITYApprovedPresentation
Two-year data from Phase 3 CAHtalyst Adult study presented at AACE 2026
classic congenital adrenal hyperplasiasource ↗
▲Full ResultsCRENESSITYApprovedClinical Data
Two-year results: 69% achieved physiologic GC dose, sustained androgen control
classic congenital adrenal hyperplasiasource ↗
▲Oral PresentationValbenazineApprovedPresentation
Real-world head-to-head claims analysis comparing INGREZZA vs AUSTEDO XR presented at AMCP 2026
tardive dyskinesiasource ↗
Past FDA Catalysts and PDUFA Decisions
How NBIX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2024-12-13 | Crenessity (crinecerfont) | PDUFA Date Approved | PDUFA |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C57 / 100
Pipeline Score
$3.1B
Pipeline Value
$13.3B
Commercial Value
Fair Value
Valuation Signal
19
Drugs Scored
0.7x
rNPV / MCap
Top 9%
Mid Cap(rank 60 of 658)
Percentile Rank
Neurocrine Biosciences, Inc. carries a moderate pipeline score (57/100), with $3.7B risk-adjusted pipeline value, led by NBI-1065845 in Major Depressive Disorder (Phase 3), across $91B in total addressable markets.
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Jun 2026; product lines: last four quarters to Jun 2026 (10-K and 10-Q)) Revenue $3.4B x 4.0 = $13.3B
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| INGREZZA | $2.7B | - | - |
| CRENESSITY | $570M | - | - |
| VYKAT XR | $54M | - | - |
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NBI-1065845 Small moleculeNCT05203341 | Major Depressive Disorder | Phase 3 | COMPLETED | 2,183 | Feb 21, 2024 |
Clinical Trial Results
Readouts, endpoints and source filings for every NBIX program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| VYKAT XR | Prader-Willi syndrome | Phase 3 | 2026-06-15 | 6.2 points at Year 1; 6.5 points at Year 2; 6.2 points at Year 3; -2.5 in anxiety; -2.4 in rigidity/irritability; -2.3 in compulsivity; -2.1 in aggressive behaviors; -1.5 in disordered thinking; -1.1 in depressionRead More | Soleno Therapeutics Presents New VYKAT® XR (diazoxide choline) Data at ENDO 2026 Demonstrating Meaningful and Durable Improvements in Hyperphagia and Behavioral Symptoms in Prader-Willi Syndrome Following Randomized Withdrawal Period Soleno Therapeutics, a Neurocrine Biosciences (Nasdaq: NBIX) company, today announced late-breaking data at ENDO 2026 showing that resuming treatment ...Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Boyer David W.Officer (Chief Corp. Affairs Officer) | Sell | -826 8,722 held | $157.45 | 09/14/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in NBIX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| RTW INVESTMENTS, LP | 1.8 % (28.6 %) | 213.69 M | 1.27 M | 19.38% ( 205.85 K) |
NBIX Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How NBIX ranks across every disease it competes in
Competitive Position is a premium feature
See how NBIX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialNBIX News
NBIXNeurocrine Biosciences to Present Research Advancing Understanding of Prader-Willi Syndrome and Real-World Experience with VYKAT® XR (diazoxide choline) at Foundation for Prader-Willi Research Symposium & Family Conference
Neurocrine Biosciences will present research on Prader-Willi syndrome and VYKAT XR at the FPWR 2026 Annual Research Symposium. The studies include the PWS-VISTA observational study, which focuses on real-world evidence of VYKAT XR, and the BRAVE-PWS study, which captures caregiver experiences. The findings aim to deepen understanding of PWS and improve treatment approaches.
Read more →NBIXNeurocrine Biosciences Appoints Eiry W. Roberts, M.D., as Chief Medical Officer
Neurocrine Biosciences has appointed Eiry W. Roberts, M.D., as Chief Medical Officer, effective immediately. Dr. Roberts, who previously held the position from 2018 to 2025, will lead the company's clinical development efforts. Her return is expected to provide continuity as Neurocrine advances several late-stage programs. Sanjay Keswani, M.D., will be departing the company by mutual agreement.
Read more →NBIXNeurocrine Biosciences to Present at Upcoming Investor Conferences in September
Neurocrine Biosciences, Inc. announced its participation in several investor conferences in September 2026. The events include the Wells Fargo 21st Annual Healthcare Conference, Cantor Global Healthcare Conference 2026, and Morgan Stanley 24th Annual Global Healthcare Conference. Executives will engage in fireside chats, and webcasts will be available for those unable to attend live.
Read more →NBIXNxera Pharma’s Partner Neurocrine Biosciences Receives IND Acceptance from the FDA for Phase 2 Study of NBI-1117567 for Alzheimer's Cognition
Neurocrine Biosciences has received IND acceptance from the FDA for NBI-1117567, an investigational drug for Alzheimer's cognition. Nxera Pharma will receive a $10 million milestone payment as part of their collaboration. NBI-1117567 is the third compound from Nxera's muscarinic agonist portfolio to advance to Phase 2, indicating progress in addressing Alzheimer's disease.
Read more →NBIXNeurocrine Biosciences Announces Publication of KINECT-PRO™ Findings Demonstrating INGREZZA® (valbenazine) Capsules Improved Patient-Reported Quality of Life and Daily Functioning for People Living with Tardive Dyskinesia
Neurocrine Biosciences announced the publication of KINECT-PRO™ findings, showing that INGREZZA® (valbenazine) significantly improves patient-reported quality of life and functionality in individuals with tardive dyskinesia (TD). The Phase 4 study revealed that 58% of participants achieved symptomatic remission by Week 24, with improvements noted across various severity levels. The results underscore the treatment's effectiveness in enhancing daily functioning and reducing movement severity.
Read more →NBIXNeurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-'1968, a GLP-1/GIP/Glucagon Receptor Triple Agonist
Neurocrine Biosciences has initiated a Phase 1 clinical study for NBIP-'1968, a triple agonist targeting GLP-1, GIP, and glucagon receptors, aimed at treating obesity. This study will assess the safety and tolerability of the drug in adult participants with varying body mass indices. The development of NBIP-'1968 is part of a broader strategy to expand Neurocrine's obesity treatment options.
Read more →NBIX▼ -10.1%on this news
Neurocrine Biosciences Reports Second-Quarter 2026 Financial Results
Neurocrine Biosciences reported a strong second-quarter performance for 2026, with total revenues increasing by 39% year-over-year to $959 million. The company raised its net sales guidance for INGREZZA, reflecting robust demand and prescription growth. Additionally, the acquisition of Soleno Therapeutics is expected to strengthen its position in the market. Positive clinical trial results for CRENESSITY further bolster the company's outlook.
Read more →NBIXNeurocrine Biosciences Announces Key Leadership Hiring, Promotions
Neurocrine Biosciences has announced the appointment of three Senior Vice Presidents to enhance its leadership as it enters a new growth phase. Bret Paulson, David Bradfute, and Aaron Vosburgh will take on key roles in market access, intellectual property, and finance, respectively. These changes aim to support the company's expanding commercial portfolio and neuroscience pipeline.
Read more →NBIXNeurocrine Biosciences Appoints Samir Siddhanti Chief Business Officer
Neurocrine Biosciences has appointed Samir Siddhanti as Chief Business Officer, where he will lead the company's growth strategy and oversee business development. Siddhanti has been with Neurocrine since 2017, playing a key role in strategic partnerships and the recent acquisition of Soleno Therapeutics. His leadership is expected to enhance the company's pipeline and drive future growth.
Read more →NBIXNeurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2026 Financial Results
Neurocrine Biosciences has announced a conference call and webcast to discuss its second quarter 2026 financial results. Scheduled for July 30, 2026, the call will begin at 1:30 p.m. PT. The company aims to provide updates on its financial performance and ongoing projects, showcasing its commitment to addressing neurological and psychiatric disorders.
Read more →NBIXNeurocrine Biosciences Initiates Phase 2 Study of Crinecerfont in Pediatric Patients Under 4 Years Old with Classic Congenital Adrenal Hyperplasia
Neurocrine Biosciences has launched a Phase 2 clinical trial for crinecerfont, targeting children under 4 years with classic congenital adrenal hyperplasia (CAH). The study aims to evaluate the drug's safety and tolerability in a vulnerable population often reliant on high glucocorticoid doses. This initiative reflects the company's commitment to improving treatment options for young patients with CAH.
Read more →NBIXNeurocrine Biosciences Presents First Retrospective Case Series of CRENESSITY® (crinecerfont) in Patients with Classic Congenital Adrenal Hyperplasia Due to 11β‑Hydroxylase Deficiency at ENDO 2026
Neurocrine Biosciences presented a retrospective case series at ENDO 2026, showcasing the effects of CRENESSITY (crinecerfont) in patients with classic congenital adrenal hyperplasia due to 11β-hydroxylase deficiency. The study revealed substantial reductions in adrenal hormone levels and glucocorticoid doses among patients. This case series provides preliminary insights into the treatment of this rare condition, emphasizing the need for further research.
Read more →NBIXNeurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Improved Growth Measures in Pediatric Patients with Classic Congenital Adrenal Hyperplasia at ENDO 2026
Neurocrine Biosciences presented two-year data on CRENESSITY (crinecerfont) at ENDO 2026, showing positive growth outcomes in pediatric patients with classic congenital adrenal hyperplasia (CAH). The study indicated slowed bone age progression and improved predicted adult height. Caregiver surveys revealed universal satisfaction and optimism regarding the treatment's impact on children's quality of life.
Read more →NBIXNeurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Improvements in Cardiometabolic Outcomes in Adults with Classic Congenital Adrenal Hyperplasia at ENDO 2026
Neurocrine Biosciences presented new data from the Phase 3 CAHtalyst Adult study at ENDO 2026, showing that CRENESSITY (crinecerfont) significantly improved cardiometabolic outcomes and reduced glucocorticoid doses in adults with classic congenital adrenal hyperplasia (CAH). Over two years, participants experienced weight loss, improved insulin resistance, and enhanced bone health. Patient surveys indicated high satisfaction and improved quality of life.
Read more →NBIXSoleno Therapeutics Presents New VYKAT® XR (diazoxide choline) Data at ENDO 2026 Demonstrating Meaningful and Durable Improvements in Hyperphagia and Behavioral Symptoms in Prader-Willi Syndrome Following Randomized Withdrawal Period Soleno Therapeutics, a Neurocrine Biosciences (Nasdaq: NBIX) company, today announced late-breaking data at ENDO 2026 showing that resuming treatment ...
Soleno Therapeutics, a Neurocrine Biosciences company, presented significant new data at ENDO 2026 regarding VYKAT XR (diazoxide choline) for treating hyperphagia in individuals with Prader-Willi syndrome. The results reveal that patients resuming treatment after a 16-week randomized withdrawal saw continued improvements in hyperphagia and behavioral symptoms. The data, derived from a comprehensive Phase 3 study, showcases that VYKAT XR provides durable benefits and statistically significant enhancements compared to a natural history control group. The drug has a history of FDA approval and is available for patients aged four and older with Prader-Willi syndrome.
Read more →NBIXNeurocrine Biosciences Presents New Data Highlighting Functional and Socio-emotional Improvements with INGREZZA® (valbenazine) Capsules in Individuals with Tardive Dyskinesia and Intellectual and Developmental Disabilities
Neurocrine Biosciences presented new data showing that nearly all individuals with intellectual and developmental disabilities experienced improvements in tardive dyskinesia severity after treatment with INGREZZA. The data, reported at a conference, highlighted rapid improvements in both TD symptoms and overall functional status, including socio-emotional outcomes. Clinicians noted significant burdens associated with TD, emphasizing the need for better recognition and treatment.
Read more →NBIXNeurocrine Biosciences Presents New Clinically Meaningful Response Data on Treatment of Tardive Dyskinesia, Reinforcing the Efficacy of INGREZZA® (valbenazine) Capsules Across a Broad Range of Patients
Neurocrine Biosciences presented new data from the KINECT®4 trial showing that 94% of patients with tardive dyskinesia treated with INGREZZA (valbenazine) experienced either symptomatic remission or clinically meaningful improvements. Additionally, a claims analysis revealed a high prevalence of hepatic risk factors among these patients, emphasizing the need for careful treatment decisions. INGREZZA remains the only VMAT2 inhibitor approved for use in patients with hepatic impairment.
Read more →NBIX▲ +6.6%on this newsshared move
Neurocrine Biosciences to Present New Two‑Year CRENESSITY® (crinecerfont) Data on Key Clinical and Patient‑Reported Outcome Measures at ENDO 2026 Analyses span adult and pediatric populations with classic congenital adrenal hyperplasia (CAH) and reflect longer-term clinical outcomes relevant to ...
Neurocrine Biosciences announced it will present new analyses of two-year outcomes for CRENESSITY (crinecerfont) in classic congenital adrenal hyperplasia (CAH) at ENDO 2026. This will cover both adult and pediatric populations, demonstrating sustained results related to androgen control and glucocorticoid exposure. The findings are expected to reinforce CRENESSITY's role as a new standard of care in managing CAH-related complications. Presentations will occur from June 13-16 in Chicago and focus on multiple clinical and patient-reported endpoints.
Read more →NBIXNeurocrine Biosciences to Present at Upcoming Investor Conferences in June
Neurocrine Biosciences, Inc. announced its participation in two upcoming investor conferences in June 2026. The events include a fireside chat at the William Blair 46th Annual Growth Stock Conference and another at the Goldman Sachs 47th Annual Global Healthcare Conference. Webcasts of these presentations will be available on the company's website.
Read more →NBIXNeurocrine Biosciences Completes Acquisition of Soleno Therapeutics
Neurocrine Biosciences has successfully completed its acquisition of Soleno Therapeutics, enhancing its portfolio with VYKAT XR, the first approved treatment for hyperphagia in Prader-Willi syndrome. The acquisition, valued at $2.9 billion, aims to address significant unmet needs in the rare disease community. VYKAT XR is now commercially available following its FDA approval in March 2025.
Read more →About Neurocrine Biosciences, Inc.
Headquarters6027 EDGEWOOD BEND COURT, SAN DIEGO, CA, 92130
BIOPHARMAWATCH ELITE PLUS
Trade the next NBIX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime